Related Experiment Video
Updated: Mar 17, 2026

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
Evolving Immunotherapy Approaches for Renal Cell Carcinoma.
Susanna A Curtis1, Justine V Cohen1, Harriet M Kluger2
1Section of Medical Oncology, Department of Medicine, Yale Cancer Center, 333 Cedar Street, PO Box 208028, New Haven, 06510, CT, USA.
Metastatic renal cell carcinoma (mRCC) remains challenging due to treatment resistance. Immune modulation therapies, including checkpoint inhibitors, offer promising durable survival benefits for patients with mRCC.
Area of Science:
- Oncology
- Immunology
Background:
- Metastatic renal cell carcinoma (mRCC) presents significant morbidity and mortality.
- Renal cell carcinoma (RCC) demonstrates resistance to traditional chemotherapy.
- Current targeted therapies offer limited durability in survival benefits.
Purpose of the Study:
- To review standard and emerging immune therapy approaches for mRCC.
- To explore combinations of immune therapies with other treatment modalities.
- To highlight the potential for prolonged survival through immune modulation.
Main Methods:
- Literature review of immune-based therapies for mRCC.
- Analysis of cytokine therapy, vaccine therapy, and cell therapy efficacy.
- Evaluation of immune checkpoint inhibitors in mRCC treatment.
Main Results:
- Immune modulation strategies show promise for durable responses in mRCC.
- Combinations of therapies may enhance survival outcomes.
- Checkpoint inhibitors represent a significant advancement in mRCC treatment.
Conclusions:
- Immune therapies offer a hopeful avenue for prolonged survival in mRCC.
- Further research into combination strategies is warranted.
- Modulating the immune system is key to overcoming RCC resistance.
More Related Videos
12:22The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers
Published on: January 22, 2013
11:08Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells
Published on: February 14, 2025
Related Concept Videos
Tumor Immunotherapy
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Treatment Resistant Cancers